Literature DB >> 20637950

Intrahepatic cholangiocarcinoma.

George A Poultsides1, Andrew X Zhu, Michael A Choti, Timothy M Pawlik.   

Abstract

Intrahepatic cholangiocarcinoma (ICC) is a primary cancer of the bile ducts, arising from malignant transformation of the epithelial cells that line the biliary apparatus. ICC is relatively uncommon, but its incidence is on the increase. ICC is frequently discovered as an incidental, indeterminate liver mass. Surgical resection of ICC represents the only potentially curative therapeutic option. The role of routine hilar lymphadenectomy is controversial, but should be considered to optimize staging. Although adjuvant chemotherapy and radiotherapy is probably not supported by current data, each should strongly be considered in patients with lymph node metastasis or an R1 resection. For those patients with inoperable disease, locoregional therapy with transarterial chemoembolization can be considered. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20637950     DOI: 10.1016/j.suc.2010.04.011

Source DB:  PubMed          Journal:  Surg Clin North Am        ISSN: 0039-6109            Impact factor:   2.741


  49 in total

Review 1.  Intra-arterial embolotherapy for intrahepatic cholangiocarcinoma: update and future prospects.

Authors:  Lynn Jeanette Savic; Julius Chapiro; Jean-François H Geschwind
Journal:  Hepatobiliary Surg Nutr       Date:  2017-02       Impact factor: 7.293

2.  Survival outcomes and prognostic factors of surgical therapy for all potentially resectable intrahepatic cholangiocarcinoma: a large single-center cohort study.

Authors:  Xianwu Luo; Lei Yuan; Yi Wang; Ruiliang Ge; Yanfu Sun; Gongtian Wei
Journal:  J Gastrointest Surg       Date:  2014-01-07       Impact factor: 3.452

3.  Locoregional recurrence after curative intent resection for intrahepatic cholangiocarcinoma: implications for adjuvant radiotherapy.

Authors:  S Song; K Kim; E K Chie; S Kim; H J Park; N J Yi; K-S Suh; S W Ha
Journal:  Clin Transl Oncol       Date:  2015-06-04       Impact factor: 3.405

Review 4.  Cholangiocarcinoma--controversies and challenges.

Authors:  Tushar Patel
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-04       Impact factor: 46.802

5.  New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing.

Authors:  Jeffrey S Ross; Kai Wang; Laurie Gay; Rami Al-Rohil; Janne V Rand; David M Jones; Hwa J Lee; Christine E Sheehan; Geoff A Otto; Gary Palmer; Roman Yelensky; Doron Lipson; Deborah Morosini; Matthew Hawryluk; Daniel V T Catenacci; Vincent A Miller; Chaitanya Churi; Siraj Ali; Philip J Stephens
Journal:  Oncologist       Date:  2014-02-21

6.  Locally Advanced Intrahepatic Cholangiocarcinoma: Complete Pathologic Response to Neoadjuvant Chemotherapy Followed by Left Hepatic Trisectionectomy and Caudate Lobectomy.

Authors:  Thuy B Tran; Chinmaya K Bal; Kurt Schaberg; Teri A Longacre; Bhupinder S Chatrath; George A Poultsides
Journal:  Dig Dis Sci       Date:  2015-04-01       Impact factor: 3.199

Review 7.  Epidemiology and risk factors: intrahepatic cholangiocarcinoma.

Authors:  Amar Gupta; Elijah Dixon
Journal:  Hepatobiliary Surg Nutr       Date:  2017-04       Impact factor: 7.293

8.  Adjuvant therapy for intrahepatic cholangiocarcinoma: the debate continues.

Authors:  Andrew X Zhu; Jennifer J Knox
Journal:  Oncologist       Date:  2012-12-07

9.  Recurrence after operative management of intrahepatic cholangiocarcinoma.

Authors:  Omar Hyder; Ioannis Hatzaras; Georgios C Sotiropoulos; Andreas Paul; Sorin Alexandrescu; Hugo Marques; Carlo Pulitano; Eduardo Barroso; Bryan M Clary; Luca Aldrighetti; Cristina R Ferrone; Andrew X Zhu; Todd W Bauer; Dustin M Walters; Ryan Groeschl; T Clark Gamblin; J Wallis Marsh; Kevin T Nguyen; Ryan Turley; Irinel Popescu; Catherine Hubert; Stephanie Meyer; Michael A Choti; Jean-Francois Gigot; Gilles Mentha; Timothy M Pawlik
Journal:  Surgery       Date:  2013-03-15       Impact factor: 3.982

10.  Expression of GLP-1R protein and its clinical role in intrahepatic cholangiocarcinoma tissues.

Authors:  Ben-Dong Chen; Wen-Chao Zhao; Jian-Da Dong; Hui Sima
Journal:  Mol Biol Rep       Date:  2014-02-28       Impact factor: 2.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.